Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Yttrium Y 90 Glass Microspheres Clear all
Completed Not applicable Interventional Results available

TheraSphere® For Treatment of Metastases in Liver

NCT04517643
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Colorectal Cancer
Interventions
Therasphere Therapy
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 30, 2026, 7:08 AM EDT
Completed No phase listed Observational

TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

NCT00683631
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere HUD
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 30, 2026, 7:08 AM EDT
No Longer Available No phase listed Expanded access

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

NCT02960620
View directory record Official record
Conditions
Liver Cancer, Liver Neoplasms, HepatoCellular Carcinoma
Interventions
TheraSphere Treatment
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

NCT03203837
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Plasma collection
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 30, 2026, 7:08 AM EDT
Completed No phase listed Observational

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT00530010
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres
Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting Not applicable Interventional

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia

NCT05953961
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Therasphere 90Y, Microwave Ablation
Device
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Early Phase 1 Interventional

Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection

NCT03812562
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Nivolumab, Yttrium Y 90 Glass Microspheres
Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 1 Interventional Results available

Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer

NCT02837029
View directory record Official record
Conditions
Stage IIIA Hepatocellular Carcinoma, Stage IIIB Hepatocellular Carcinoma, Stage IIIC Hepatocellular Carcinoma, Stage IVA Hepatocellular Carcinoma, Stage IVB Hepatocellular Carcinoma
Interventions
Laboratory Biomarker Analysis, Nivolumab, Yttrium Y 90 Glass Microspheres
Other · Biological · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 30, 2026, 7:08 AM EDT
Active, not recruiting Phase 2 Interventional

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

NCT06040099
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
Drug · Procedure
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
Aurora, Colorado • Gainesville, Florida • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Completed No phase listed Observational

A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®

NCT00877136
View directory record Official record
Conditions
Liver Tumors, Hepatocellular Carcinoma, Hepatoma, Neoplasms
Interventions
TheraSphere®
Device
Lead sponsor
St. Joseph Hospital of Orange
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 30, 2026, 7:08 AM EDT
Recruiting Phase 2 Interventional

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

NCT05620771
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Y90 + Atezolizumab and Bevacizumab, Y90 + TKI
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
7
States / cities
Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Active, not recruiting Not applicable Interventional

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

NCT05953337
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
Interventions
EYE90 Microspheres Treatment
Device
Lead sponsor
ABK Biomedical
Industry
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
21
States / cities
Tucson, Arizona • Orange, California • Altamonte Springs, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 30, 2026, 7:08 AM EDT
Not listed Phase 2 Interventional

A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.

NCT00152087
View directory record Official record
Conditions
Liver Cancer
Interventions
Brachytherapy
Device
Lead sponsor
St. Joseph's Hospital, Florida
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2005 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Phase 2 Interventional Results available

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT04541173
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Y-90 TARE, Atezolizumab, Bevacizumab
Other · Drug
Lead sponsor
Aiwu Ruth He, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Not applicable Interventional Results available

Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors

NCT03109262
View directory record Official record
Conditions
Primary Malignant Liver Neoplasm
Interventions
Computed Tomography (CT), Positron Emission Tomography (PET), 90-Yttrium (Y-90) Glass Microspheres, Technetium 99mTc albumin aggregated (99mTc-MAA), Single-photon emission computerized tomography (SPECT) scan
Procedure · Device · Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets

NCT01581307
View directory record Official record
Conditions
Liver Cancer, Pancreatic Cancer
Interventions
FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), TheraSpheres
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Not applicable Interventional Results available

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

NCT03059030
View directory record Official record
Conditions
Thrombocytopenia, Cirrhosis
Interventions
TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 30, 2026, 7:08 AM EDT
Completed Not applicable Interventional Results available

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

NCT01556490
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
TheraSphere
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Tampa, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Early Phase 1 Interventional

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

NCT01730157
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 30, 2026, 7:08 AM EDT
Approved For Marketing No phase listed Expanded access

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

NCT01076517
View directory record Official record
Conditions
Liver Cancer
Interventions
Therasphere
Device
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 30, 2026, 7:08 AM EDT
Terminated Phase 1 Interventional

Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

NCT01434459
View directory record Official record
Conditions
Pancreatic Neoplasms, Cholangiocarcinoma
Interventions
Gemcitabine with TheraSphere
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 30, 2026, 7:08 AM EDT
Not listed Early Phase 1 Interventional

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

NCT03099564
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Pembrolizumab, Y90 radioembolization
Drug · Device
Lead sponsor
Ashwin Somasundaram
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 30, 2026, 7:08 AM EDT
Approved For Marketing No phase listed Expanded access

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

NCT00906984
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Primary Liver Cancer
Interventions
TheraSphere
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 30, 2026, 7:08 AM EDT
Not listed Phase 2 Interventional

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

NCT00436267
View directory record Official record
Conditions
Metastatic Cancer, Pancreatic Cancer
Interventions
fluorouracil, selective external radiation therapy, tomotherapy, yttrium Y 90 glass microspheres, yttrium Y 90 resin microspheres
Drug · Radiation
Lead sponsor
Goshen Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Goshen, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 30, 2026, 7:08 AM EDT